Stockscreener 앱 받기
5.82
4.68%
0.26
시간 외 거래:
5.90
0.08
+1.37%
전일 마감가:
$5.56
열려 있는:
$5.47
하루 거래량:
2.19M
Relative Volume:
1.21
시가총액:
$511.20M
수익:
$30.91M
순이익/손실:
$-209.47M
주가수익비율:
-1.7489
EPS:
-3.3279
순현금흐름:
$-147.13M
1주 성능:
-0.34%
1개월 성능:
-2.02%
6개월 성능:
-35.69%
1년 성능:
-16.62%
1일 변동 폭
$5.31
$5.97
1주일 범위
$5.31
$6.00
52주 변동 폭
$4.01
$11.24
Verastem Inc Stock (VSTM) Company Profile
명칭
Verastem Inc
전화
(781) 292-4200
주소
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.82 | 488.36M | 30.91M | -209.47M | -147.13M | -3.3279 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | BTIG Research | Buy |
| 2026-02-04 | 개시 | H.C. Wainwright | Buy |
| 2025-10-16 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-10 | 개시 | Jefferies | Buy |
| 2025-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-31 | 재확인 | BTIG Research | Buy |
| 2024-09-30 | 개시 | Guggenheim | Buy |
| 2023-11-21 | 재개 | BTIG Research | Buy |
| 2023-09-27 | 개시 | B. Riley Securities | Buy |
| 2023-06-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-07 | 재개 | Alliance Global Partners | Buy |
| 2022-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-09 | 개시 | Truist | Buy |
| 2021-07-01 | 개시 | Alliance Global Partners | Buy |
| 2021-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2019-06-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 개시 | BTIG Research | Buy |
| 2018-05-02 | 개시 | Seaport Global Securities | Buy |
| 2018-03-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-13 | 개시 | Oppenheimer | Outperform |
| 2017-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2015-09-29 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-09-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2015-09-28 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-05-12 | 재확인 | UBS | Buy |
| 2015-04-08 | 개시 | H.C. Wainwright | Buy |
| 2015-01-23 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Oppenheimer | Perform |
| 2014-02-11 | 개시 | Mizuho | Buy |
모두보기
Verastem Inc 주식(VSTM)의 최신 뉴스
Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play (NASDAQ:VSTM) - Seeking Alpha
AACR Meeting spotlights Verastem, Inc. progress on oral KRAS G12D inhibitor - Traders Union
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 - Business Wire
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers - Business Wire
Foresite Capital Management VI LLC Has $23.09 Million Holdings in Verastem, Inc. $VSTM - MarketBeat
Verastem (NASDAQ:VSTM) Stock Rating Upgraded by BTIG Research - MarketBeat
Discipline and Rules-Based Execution in VSTM Response - Stock Traders Daily
Why did Verastem stock jump after-hours despite an earnings miss? - MSN
Verastem (VSTM) Q4 2025 Earnings Call Transcript - AOL.com
Verastem's (VSTM) Buy Rating Reaffirmed at BTIG Research - MarketBeat
VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Verastem stock initiated at Buy by BTIG with $19 price target - Investing.com Canada
Verastem stock initiated at Buy by BTIG with $19 price target By Investing.com - Investing.com India
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High? - Yahoo Finance
Verastem (VSTM) reports Q4 loss, beats revenue estimates - MSN
Jefferies Financial Group Inc. Increases Stake in Verastem, Inc. $VSTM - MarketBeat
Earnings call transcript: Verastem’s Q4 2025 results highlight oncology growth - Investing.com Nigeria
Verastem Earnings Call: Early Momentum, Long Runway Risks - TipRanks
Verastem (NASDAQ:VSTM) Raised to Hold at Wall Street Zen - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN), Verastem (VSTM) and Align Tech (ALGN) - The Globe and Mail
Jefferies Maintains Buy on Verastem, Inc. (VSTM) March 2026 - Meyka
Verastem (VSTM) Q4 Revenue Debut Highlights Ongoing Losses And Tests Bullish Profitability Timeline - simplywall.st
Verastem 2025 Financial Results: Q4 and Annual Revenue & LossNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Jefferies reiterates Verastem stock rating on launch progress By Investing.com - Investing.com Canada
Verastem, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and Financial Challenges - GuruFocus
Verastem Q4 2025 Earnings Call Transcript - MarketBeat
Verastem Q4 Earnings Call Highlights - MarketBeat
Verastem: Fourth Quarter Financial Results Overview - Bitget
Verastem (VSTM) Reports Strong Q4 2025 Earnings and Progress in Clinical Trials - GuruFocus
Key Developments for Verastem (VSTM) in 2026 Clinical Trials - GuruFocus
Verastem Highlights AVMAPKI FAKZYNJA Strategy and Pipeline Risks - TipRanks
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Verastem (VSTM) Reports Strong Revenue and Advances Cancer Treat - GuruFocus
Verastem (NASDAQ:VSTM) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Verastem: Q4 Earnings Snapshot - KVUE
Verastem, Inc. releases Q4 and year end 2025 results with business update - Traders Union
Verastem (VSTM) shares updated March 4, 2026 corporate presentation - Stock Titan
Earnings Summary: Verastem Q4 - Benzinga
Verastem (NASDAQ: VSTM) grows LGSOC launch and advances KRAS G12D programs - Stock Titan
Verastem, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings Outlook For Verastem - Benzinga
VSTM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Verastem (VSTM): Can This Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
Verastem Inc (VSTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):